索拉非尼对宫颈癌HeLa细胞增殖的影响及其抑癌机制探讨

发布时间：2018-05-17 14:21

本文选题：索拉非尼 + 宫颈癌　；参考：《中国临床药理学杂志》2017年15期

【摘要】：目的研究索拉非尼对宫颈癌He La细胞增殖的抑制作用,并对其抑癌机制进行初步探讨。方法用终浓度为0.01,0.1,1.0,2.5,5.0 mg·L~(-1)的索拉非尼干预宫颈癌He La细胞(实验组),无任何药物处理的宫颈癌He La细胞为对照组,培养1,2,3 d后,用溴化四唑蓝比色(MTT)法检测各组宫颈癌He La细胞增殖情况,用细胞免疫荧光法检测及酶联免疫吸附实验(ELISA)法检测各组血管内皮生长因子-C(VEGF-C)和磷酸化细胞外信号调节激酶(p-ERK)蛋白表达情况。结果培养3 d后,对照组、0.01,0.1,1.0,2.5,5.0 mg·L~(-1)实验组的细胞增殖抑制率分别为(5.15±1.67)%,(9.16±1.58)%,(23.07±1.86)%,(30.86±2.67)%,(55.94±3.92)%,(68.75±4.48)%。实验组与对照组比较,差异有统计学意义(P0.01)。实验组细胞培养3 d的增殖抑制率与培养1d比较,差异有统计学意义(P0.05)。细胞免疫荧光检测结果显示,对照组中绿色荧光明显增强,经不同浓度索拉非尼处理后,绿色荧光明显减弱。对照组、0.01,0.1,1.0 mg·L~(-1)实验组的VEGF-C分别为(1326.54±139.57),(1305.64±119.82),(1235.57±102.34),(1083.33±89.61)pg·m L~(-1);对照组、0.01,0.1,1.0 mg·L~(-1)实验组的p-ERK分别为(2.34±0.28),(2.21±0.22),(1.56±0.21),(0.96±0.13)μg·m L~(-1)。实验组的VEGF-C和p-ERK蛋白表达量明显低于对照组(P0.05),且VEGF-C和p-ERK的表达随药物浓度的增加而逐渐降低,差异有统计学意义(P0.05)。结论索拉非尼可抑制宫颈癌He La细胞增殖,且抑制率与其作用时间、浓度呈正比,其抑癌机制可能与其能够抑制宫颈癌He La细胞VEGF-C和p-ERK蛋白表达相关。
[Abstract]:Objective to study the inhibitory effect of Solafenib on the proliferation of cervical cancer cell line he La and its mechanism. Methods Sorafenil (final concentration was 0.01g / ml) was used to interfere with cervical cancer He-La cells (experimental group, control group, without any drug treatment), and cultured for 1 day, 2 days later, after 3 days of culture, helafenil was used to treat cervical cancer He-La cells, the control group was treated with helafenil as the control group, and the He-La cells were cultured for 3 days. The proliferation of helium La cells in each group was detected by MTT assay. The expression of vascular endothelial growth factor (VEGF-C) and phosphorylated extracellular signal-regulated kinase (pERK) protein were detected by cell immunofluorescence assay and enzyme linked immunosorbent assay (Elisa). Results after 3 days of culture, the cell proliferation inhibition rate of the control group was 0.01 卤1.50 mg / L, and the inhibitory rate was 5.15 卤1.67 and 23.07 卤1.866.86 卤3.922 卤3.922 卤4.48. The inhibition rate of cell proliferation in the experimental group was 55.94 卤3.922 and 68.75 卤4.48, respectively. The difference between the experimental group and the control group was statistically significant (P 0.01). The proliferation inhibition rate of the experimental group was significantly higher than that of the 1 day culture group (P 0.05). The results of cell immunofluorescence assay showed that the green fluorescence in the control group was significantly increased, and the green fluorescence was significantly decreased after different concentrations of Solafenib. The VEGF-C of the control group was 1326.54 卤139.57 卤1305.64 卤119.82 卤1235.57 卤1083.33 卤1083.33 卤1083.33 卤89.61)pg / L, respectively, and the p-ERK of the control group was 2.34 卤0.28 mg / L, respectively. The p-ERK of the experimental group was 2.34 卤0.28 (1.56 卤0.21 卤0.96 卤0.13) 渭 g / mL. The expression of VEGF-C and p-ERK protein in the experimental group was significantly lower than that in the control group (P 0.05), and the expression of VEGF-C and p-ERK decreased gradually with the increase of drug concentration. The difference was statistically significant (P 0.05). Conclusion Solafenil can inhibit the proliferation of He-La cells, and the inhibition rate is directly proportional to the time and concentration of the inhibition. The mechanism of the inhibition may be related to the inhibition of the expression of VEGF-C and p-ERK proteins in He-La cells.
【作者单位】：三亚市人民医院妇产科;三亚市人民医院病理科;
【基金】：海南省医药卫生科研基金资助项目(1402000320A2006)
【分类号】：R96

【参考文献】